Identification of broadly tumour-reactive γδ TCRs from multiple myeloma

Researchers have identified broadly tumor-reactive γδ T cell receptors (TCRs) in multiple myeloma, highlighting their potential for universal cancer immunotherapy without HLA matching. These γδ T cells may complement existing treatments like belantamab mafodotin by enhancing adaptive immune responses.